The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition
- PMID: 18215140
- DOI: 10.1042/BJ20071430
The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition
Abstract
ADAM (a disintegrin and metalloproteinase) 10 is a key member of the ADAM family of disintegrin and metalloproteinases which process membrane-associated proteins to soluble forms in a process known as 'shedding'. Among the major targets of ADAM10 are Notch, EphrinA2 and CD44. In many cell-based studies of shedding, the activity of ADAM10 appears to overlap with that of ADAM17, which has a similar active-site topology relative to the other proteolytically active ADAMs. The tissue inhibitors of metalloproteinases, TIMPs, have proved useful in the study of ADAM function, since TIMP-1 inhibits ADAM10, but not ADAM17; however, both enzymes are inhibited by TIMP-3. In the present study, we show that, in comparison with ADAM17 and the MMPs (matrix metalloproteinases), the N-terminal domains of TIMPs alone are insufficient for the inhibition of ADAM10. This knowledge could form the basis for the design of directed inhibitors against different metalloproteinases.
Similar articles
-
ADAM17 co-purifies with TIMP-3 and modulates endothelial invasion responses in three-dimensional collagen matrices.Matrix Biol. 2009 Oct;28(8):470-9. doi: 10.1016/j.matbio.2009.07.007. Epub 2009 Aug 8. Matrix Biol. 2009. PMID: 19666115
-
Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.Clin Exp Metastasis. 2011 Dec;28(8):793-802. doi: 10.1007/s10585-011-9410-z. Epub 2011 Jul 26. Clin Exp Metastasis. 2011. PMID: 21789719
-
Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.Cancer Res. 2009 Oct 15;69(20):8050-7. doi: 10.1158/0008-5472.CAN-09-0789. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826051
-
The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.Semin Cell Dev Biol. 2009 Apr;20(2):164-74. doi: 10.1016/j.semcdb.2008.09.005. Epub 2008 Sep 18. Semin Cell Dev Biol. 2009. PMID: 18951988 Review.
-
The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?Eur J Cell Biol. 2011 Jun-Jul;90(6-7):527-35. doi: 10.1016/j.ejcb.2010.11.005. Epub 2010 Dec 30. Eur J Cell Biol. 2011. PMID: 21194787 Review.
Cited by
-
ADAM17 Mediates Proteolytic Maturation of Voltage-Gated Calcium Channel Auxiliary α2δ Subunits, and Enables Calcium Current Enhancement.Function (Oxf). 2022 Mar 17;3(3):zqac013. doi: 10.1093/function/zqac013. eCollection 2022. Function (Oxf). 2022. PMID: 35462614 Free PMC article.
-
Functional characterization of tissue inhibitor of metalloproteinase-1 (TIMP-1) N- and C-terminal domains during Xenopus laevis development.ScientificWorldJournal. 2014 Jan 30;2014:467907. doi: 10.1155/2014/467907. eCollection 2014. ScientificWorldJournal. 2014. PMID: 24616631 Free PMC article.
-
Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).Biochem J. 2010 Aug 15;430(1):79-86. doi: 10.1042/BJ20100649. Biochem J. 2010. PMID: 20533908 Free PMC article.
-
The ADAM metalloproteinases.Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008 Aug 15. Mol Aspects Med. 2008. PMID: 18762209 Free PMC article. Review.
-
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.Biochim Biophys Acta. 2010 Jan;1803(1):55-71. doi: 10.1016/j.bbamcr.2010.01.003. Epub 2010 Jan 15. Biochim Biophys Acta. 2010. PMID: 20080133 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous